CISPLATIN (CDDP) AND HEARING DISORDER
1987 Volume 30 Issue 1 Pages 61-67
Details
1987 Volume 30 Issue 1 Pages 61-67
Cisplatin was administered intravenously or intraperitoneally to patients with gynecological malignant tumors, and investigated its effect on the auditory organ. The results were as follows.
1. Auditory acuity was deteriorated by 20 dB or more in 26.1% of the total, 22.2% of patients given intravenous doses and 28.6% of patient given intraperitoneal doses. Deterioration of 25 dB or more occurred in 17.4%, 11.1% and 21.4% respectively.
2. Hearing disorder developed at an average dose of 190 mg.
3. Intravenous administration caused hearing disorder at lower doses than in intraperitoneal administration.
4. In patients under the age of 60 years, intraperitoneal administration was safer.
5. With regard to frequency, hearing was most frequently disturbed at 8 kHz.
6. No vestibular disturbance was found.
